---
layout: post
title: "Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:58:49 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-07978
original_published: 2022-04-14 00:00:00 +0000
significance: 8.00
---

# Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 14, 2022 00:00 UTC
**Document Number:** 2022-07978

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials." The purpose of this guidance is to provide recommendations to sponsors developing medical products on the approach for developing a Race and Ethnicity Diversity Plan (referred to as the "Plan") to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic populations in the United States.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/14/2022-07978/diversity-plans-to-improve-enrollment-of-participants-from-underrepresented-racial-and-ethnic)
- API: https://www.federalregister.gov/api/v1/documents/2022-07978

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
